DEENOVA
16.1.2023 06:01:50 CET | Business Wire | Press release
Deenova confirms its undisputed leadership on the French Hospital Pharmacy Automation market by announcing six new contract awards in France of 10 market leading D3 ACCED mechatronic solutions through the previous victory at competitive UNIHA tender. Three have been awarded by both the Centre Hospitalier de Béziers and the Centre Hospitalier de Troyes, one has been awarded by the Etablissement public départemental de santé de Gorze, by the Etablissement public de santé mentale de l’Aube at Brienne-Le- Château, by the Centre Hospitalier Alpes-Leman at Contamine-sur-Arve, and finally by the Hôpital de Sallanches.
Loïc Bessin, Managing Director of Deenova France, proudly stated: “This is the best way to start 2023, and confirms our undisputed leadership in France. More than 50 healthcare institutions have chosen our robots, because of their reliability, speed and ease of use. We expect this trend to continue and even accelerate as the demand for solution to secure medication is growing significantly.”
Christophe Jaffuel, Chief Commercial Officer of Deenova, said: “I am extremely proud of the results of our French organization, that has been scoring 3 years of record sales consecutively. France has been a major contributor to the European revenue growth of the company, together with successful market entries in Germany, Spain, UK and Poland.”
The Centre Hospitalier de Béziers is part of the Groupement Hospitalier de Territoire Ouest-Hérault, in the Occitanie region of southern France, providing emergency assistance, surgical and medical specialties, psychological support and screenings.
Gorze is a commune of the Grand Est Region in north-eastern France and the Etablissement public départemental de santé has 310 beds.
In the Grand Est Region there is also the Etablissement public de santé mentale de l’Aube at Brienne-Le- Château, an adult psychiatric clinic with day hospital, geronto psychiatry beds and a medium term unit receiving prisoners.
Centre Hospitalier de Troyes is in the capital of the Aube department and has 11 centers covering all medical, surgical and medico-technical disciplines, with more than 1,000 beds.
Contamine-sur-Arve is a commune in the Auvergne-Rhône-Alpes region of eastern France. The Centre Hospitalier Alpes-Leman has 700 beds and places with more than 2,000 professionals assisting 1,300 people every day.
The Hôpital de Sallanches is one of the 5 sites of the Hôpitaux du Pays du Mont Blanc, all located in the heart of 3 worldwide famous ski areas, at the foot of Mont-Blanc, in the Haute-Savoie department. More than 1,000 health professionals working in 6 committed poles, from Surgery & Acute Care to Geriatrics, provide health coverage to 120,000 permanent inhabitants and many seasonal tourists.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%.
Please visit www.deenova.com for additional information on its market leading solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230115005028/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EIG’s MidOcean Energy Announces Initial Equity Raise of $1.2 billion Versus $1.0 billion Cover17.3.2026 08:26:00 CET | Press release
MidOcean Energy (“MidOcean” or the “Company”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced an equity capital raise of more than $1.2 billion. This equity raise includes: a $500 million commitment from Idemitsu Kosan, a highly respected global energy company with a long-standing presence across the energy value chain; and additional commitments of $790 million from both new and existing investors. This represents a significant milestone in MidOcean’s capital formation program and reflects continued interest from both new and existing investors in the Company’s strategy to seek to build a diversified, resilient, long-life global LNG platform. There is significant further momentum from additional investors currently in documentation. MidOcean will continue to raise capital, with a cumulative target of up to $2 billion from new investors. The Company has received substantial interest from investors seeking long-term exposure to the LNG sector, supported
RS2 Launches “Beyond by RS2” to Power the Next Generation of European Fintech17.3.2026 08:00:00 CET | Press release
RS2, a Tier-1 global provider of payment processing infrastructure and technology solutions, today announced the launch of Beyond by RS2, a new digital payments brand designed to help fintech companies, platforms, and payment providers rapidly launch card issuing and payment acceptance services across Europe. Built on RS2’s globally proven BankWORKS platform, Beyond by RS2 offers fintechs a comprehensive sponsored issuer and acquiring program, enabling partners to issue cards and process payments without needing their own banking license or direct card scheme membership. The program leverages RS2’s Electronic Money Institution (EMI) license in Germany and its principal membership with Visa and Mastercard, allowing fintech partners to operate under RS2’s regulated infrastructure while maintaining their own customer experience and brand. “Beyond by RS2 represents a major step in our strategy to enable innovation in payments,” said Radi El Haj, CEO, RS2. “Fintechs today want to build powe
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G Nfl Blood Assay17.3.2026 07:00:00 CET | Press release
H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter “Fujirebio”) today announced that Fujirebio Europe N.V. has obtained a CE Certificate of the Lumipulse G NfL Blood assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Neurofilament light chain (NfL) in plasma and serum. “While our assay menu already features many powerful disease-specific biomarkers, NfL marks a major breakthrough: our first CE-marked blood test that empowers clinicians with insights across a wide range of neurological disorders,” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “We are excited to bring this test to our customers, further expanding our comprehensive portfolio of fully automated neurological disease testing solutions on the LUMIPULSE G platform. We continue to partner with organizations and clinical experts across the wor
H2SITE Appoints Javier Cavada as New Chairman of the Board of Directors17.3.2026 07:00:00 CET | Press release
H2SITE, a technology company delivering hydrogen production and separation solutions, announces the appointment of Javier Cavada as the new Chairman of the Board of Directors. Javier joins H2SITE at a strategic phase of accelerated industrial deployment and scale-up of its hydrogen solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316654723/en/ With more than 25 years of international leadership in the energy and industrial sectors, Javier brings extensive experience in industrialising complex technologies, building high-performance organisations, and scaling large-scale energy platforms. He currently serves as President and Chief Executive Officer of Mitsubishi Power EMEA. His track record also includes serving as CEO and President of Highview Power, as well as spending 17 years at Wärtsilä Corporation, where he held senior executive roles including President of the Energy division and a member of the global Exec
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies17.3.2026 07:00:00 CET | Press release
Galderma will present nine posters spanning its full aesthetics portfolio at AMWC 2026, highlighting the regenerative benefits of Sculptra®, the long-lasting efficacy of Restylane®, and the advanced clinical performance of Relfydess® (RelabotulinumtoxinA) 1-9 The data reinforce Galderma’s future-focused approach to innovation, addressing emerging patient needs from menopause‑related skin changes to rising interest in body injectables and regenerative treatments A series of symposia and Masterclasses will further highlight Galderma’s leadership in aesthetics, showcasing how the portfolio supports complex patient profiles and evolving global trends Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scientific data across its aesthetics portfolio, alongside three symposia, and multiple Masterclasses and Meet‑the‑Expert sessions, all highlighting the expanding benefits of Sculptra, R
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom